Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia

被引:30
|
作者
Figge, David A. [1 ]
Jaunarajs, Karen L. Eskow [1 ]
Standaert, David G. [1 ]
机构
[1] Univ Alabama Birmingham, Ctr Neurodegenerat & Expt Therapeut, Dept Neurol, Birmingham, AL 35294 USA
来源
JOURNAL OF NEUROSCIENCE | 2016年 / 36卷 / 24期
关键词
DNA methylation; dyskinesia; L-DOPA; DOPA-INDUCED DYSKINESIA; PARKINSONS-DISEASE; GENE-EXPRESSION; PROJECTION NEURONS; NUCLEUS-ACCUMBENS; MEMORY FORMATION; PLASTICITY; 5-HYDROXYMETHYLCYTOSINE; DEMETHYLATION; TRANSCRIPTION;
D O I
10.1523/JNEUROSCI.0683-16.2016
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Levodopa-induced dyskinesia (LID) is a persistent behavioral sensitization that develops after repeated levodopa (L-DOPA) exposure in Parkinson disease patients. LID is a consequence of sustained changes in the transcriptional behavior of striatal neurons following dopaminergic stimulation. In neurons, transcriptional regulation through dynamic DNA methylation has been shown pivotal to many long-term behavioral modifications; however, its role in LID has not yet been explored. Using a rodent model, we show LID development leads to the aberrant expression of DNA demethylating enzymes and locus-specific changes to DNA methylation at the promoter regions of genes aberrantly transcribed following L-DOPA treatment. Looking for dynamic DNA methylation in LID genome- wide, we used reduced representation bisulfite sequencingand found an extensive reorganization of the dorsal striatal methylome. LID development led to significant demethylation at many important regulatory areas of aberrantly transcribed genes. We used pharmacologic treatments that alter DNA methylation bidirectionally and found them able to modulate dyskinetic behaviors. Together, these findings demonstrate that L-DOPA induces widespread changes to striatal DNA methylation and that these modifications are required for the development and maintenance of LID.
引用
收藏
页码:6514 / 6524
页数:11
相关论文
共 50 条
  • [31] Levodopa-Induced Dyskinesia: "TRAP"ping the Culprit
    Prasad, Shweta
    Pal, Pramod Kumar
    MOVEMENT DISORDERS, 2018, 33 (05) : 761 - 761
  • [33] Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
    Dhanya Vijayakumar
    Joseph Jankovic
    Drugs, 2016, 76 : 759 - 777
  • [34] Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
    Vijayakumar, Dhanya
    Jankovic, Joseph
    DRUGS, 2016, 76 (07) : 759 - 777
  • [35] The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia
    Molchadski, I.
    Korczyn, A. D.
    Cohen, O. S.
    Katzav, A.
    Nitzan, Z.
    Chapman, J.
    Hassin-Baer, S.
    ACTA NEUROLOGICA SCANDINAVICA, 2011, 123 (02): : 117 - 121
  • [36] Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia
    Thomas Müller
    Jan-Dominique Möhr
    Drugs, 2019, 79 : 1367 - 1374
  • [38] Striatal histone modifications in models of levodopa-induced dyskinesia
    Nicholas, A. P.
    Lubin, F. D.
    Hallett, P. J.
    Vattem, P.
    Ravenscroft, P.
    Bezard, E.
    Zhou, S.
    Fox, S. H.
    Brotchie, J. M.
    Sweatt, J. D.
    Standaert, D. G.
    JOURNAL OF NEUROCHEMISTRY, 2008, 106 (01) : 486 - 494
  • [39] Cortical gamma oscillations as biomarkers for levodopa-induced dyskinesia
    Guettler, C.
    Altschueler, J.
    Tanev, K.
    Boeckmann, S.
    Haumesser, J. K.
    Kuehn, A.
    van Riesen, C.
    MOVEMENT DISORDERS, 2019, 34
  • [40] Objective measurement of levodopa-induced dyskinesia with a force plate
    Chung, K. A.
    Lobb, B.
    Horak, F.
    Nutt, J. G.
    MOVEMENT DISORDERS, 2008, 23 (01) : S354 - S354